FDA Breast Implant Recalls: Allergan, BIA-ALCL, and the 580,000-Report MAUDE Record

Executive Summary

Breast implants are the device family where an aesthetic, quality-of-life product acquired a cancer-safety label. Our analysis of the complete FDA recall, enforcement, 510(k), PMA, and MAUDE record for the breast-implant product-code family finds a category reshaped by a single recall and a rare-but-serious lymphoma:

• 39 FDA enforcement actions match breast implant and tissue-expander devices, of which 16 are Class I — driven almost entirely by the July 2019 Allergan BIOCELL textured-implant worldwide recall that accounts for 20 of the 2019 enforcement entries — alongside 19 Class II and 4 Class III actions
• 23 recall events are recorded under the breast-implant product codes, with Allergan (14) and Inamed (3, the legacy Allergan entity) carrying the majority; "unknown/undetermined by firm" and labeling errors lead the root-cause categories
• The MAUDE adverse-event record is the largest of any aesthetic device family: we count 580,684 device-event reports across 2015–2026, including 308 death reports and 574,586 injury reports, with annual volume surging from 686 reports in 2015 to 67,401 in 2019 amid the BIA-ALCL awareness and reporting campaigns
• The defining safety fact sits outside the raw MAUDE count: the FDA separately records 1,380 unique BIA-ALCL cases and 64 BIA-ALCL deaths as of June 30, 2024, overwhelmingly associated with textured-surface implants — the evidence base that drove the Allergan BIOCELL recall

For aesthetic-device, quality, and regulatory teams, the takeaway is specific: breast implants are Class III PMA devices whose post-market burden is dominated by capsular contracture and implant-failure complication reports from two manufacturers (Allergan and Mentor), layered on top of a textured-implant lymphoma risk that effectively removed macro-textured products from the U.S. market.

Why Breast Implants Are Class III PMA Devices

Breast implants are Class III high-risk devices that require premarket approval. Our data confirms the pathway: only 2 510(k) clearances appear under the implant product codes (neither for the implants themselves), versus 400 PMA records — 9 original approvals plus supplements — dominated by Allergan (139), Mentor Worldwide (110) and Mentor Corp (78), with newer entrants Tiger Aesthetics (43), Bimini Health Tech (27), and Motiva USA (3). The approved-implant trade names — Natrelle, MemoryGel, MemoryShape, Sientra, Inspira, and Motiva SmoothSilk — map directly to the brands that dominate the MAUDE record.

This analysis covers the breast-implant product-code family:

Both FTR (silicone gel) and FWM (saline) are Class III PMA devices. The MAUDE analysis below also captures reports identified by brand and generic name (e.g., "breast implant," "mammary implant") to include tissue-expander and texturing-specific reports that may carry a different code.

The Allergan BIOCELL Recall and the BIA-ALCL Evidence Base

The breast-implant regulatory story turns on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) — a rare T-cell non-Hodgkin lymphoma of the immune system (not breast cancer) that arises in the scar capsule around an implant. The FDA first reported a possible link between breast implants and ALCL in 2011 (American Cancer Society).

The FDA's medical-device-report (MDR) evidence accumulated over the following decade. As of June 30, 2024, the FDA records 1,380 unique BIA-ALCL cases and 64 deaths, with 73% of cases involving textured-surface implants and only 3% smooth-surface; silicone-gel fill accounted for 67% and saline for 26%, and approximately 86% of cases were associated with Allergan textured implants (FDA, Medical Device Reports of BIA-ALCL; Breast Implant Safety Alliance). The clinical presentation is most often a delayed seroma (fluid collection) or swelling years after implantation — median time from last implant to diagnosis of about 8 years.

On July 24–25, 2019, after reviewing updated global safety information, the FDA requested that Allergan voluntarily recall its BIOCELL textured breast implants and tissue expanders worldwide; Allergan agreed. The recall covered the Natrelle saline-filled, Natrelle silicone-filled, Natrelle 410 highly cohesive anatomically shaped silicone-filled implants, and the Natrelle 133 tissue-expander line. Allergan's smooth and MICROCELL implants were not affected (FDA, 2019; American Cancer Society). The FDA did not recommend removal of asymptomatic textured implants.

The enforcement data reflects the event precisely: of the 39 breast-implant enforcement reports, 20 are dated 2019, and the Allergan Class I entries cite "notification by the U.S. FDA of" the BIA-ALCL association as the trigger.

Data Source and Method

• Sources: FDA device enforcement report database (Class I/II/III classification and reason-for-recall text), FDA Medical Device Recall database (recall initiation records by product code), FDA 510(k) and PMA databases, and the FDA MAUDE adverse-event database; FDA BIA-ALCL medical-device-report summary for cancer-specific case and death counts
• Analysis sample: 39 enforcement-report records whose product description and reason-for-recall text matches breast implant and tissue-expander devices; 23 recall events under the FTR and FWM product codes; 2 510(k) clearances and 400 PMA records under the same codes; 580,684 MAUDE device-event reports across 2015–2026 identified by the FTR/FWM product codes or by breast-implant brand/generic-name text
• Run date: 2026-06-15
• Method: All counts were computed by MedDeviceGuide from the public FDA enforcement, recall, 510(k), PMA, and MAUDE extracts. Enforcement records do not carry a populated product-code field, so breast-implant records were identified by text matching; firm names are reproduced as recorded by FDA. The all-cause MAUDE death and injury counts (308 deaths, 574,586 injuries) are distinct from the FDA's cancer-specific BIA-ALCL figures (64 deaths, 1,380 cases as of 6/30/2024) and should not be conflated. MAUDE event-type counts reflect reports filed, not confirmed causal attributions.

The Enforcement and Recall Footprint

Across the 39 breast-implant enforcement actions, the classification split is unusually Class I-heavy for a non-life-sustaining device, because the BIA-ALCL association upgraded the Allergan textured-implant actions to the highest severity:

Enforcement activity was concentrated in 2019 (20 actions, the BIOCELL recall year) and has re-emerged in 2026 (7 actions in the partial-year extract), indicating continued post-market activity around breast-implant labeling, capsular contracture, and rupture. The 23 recall events under the FTR/FWM codes are concentrated in Allergan:

The root-cause categories are unusual: "unknown / undetermined by firm" leads (11), reflecting that many breast-implant actions are advisory communications about risk rather than identified manufacturing defects, followed by labeling errors and process-control issues.

The MAUDE Adverse-Event Record

The MAUDE database shows both the complication burden and the reporting-campaign effect. We count 580,684 device-event reports across 2015–2026, including 308 death reports, 574,586 injury reports, and 5,659 malfunction reports.

The annual trend is the clearest reporting-campaign signature in any device family we have analyzed — a near-100-fold increase from 686 reports in 2015 to 67,401 in 2019, driven by the FDA's September 2018 letter requesting that manufacturers and facilities report BIA-ALCL and systemic-symptom cases, the BIA-ALCL awareness campaigns, and the July 2019 Allergan recall. An academic cross-sectional analysis of roughly 2.2 million MAUDE breast-implant reports from 2010–2024 found reports rose 112.5-fold after the recall and remained elevated at about 119-fold through 2024, with a 414-fold rise in capsular-contracture reports, a 214-fold rise in rupture reports, and a 40-fold rise in infection reports — while BIA-ALCL reports decreased both absolutely (from 487 in 2019 to 357 in 2024) and proportionally (from 1.96% to 1.35% of total reports), concluding that spontaneous-reporting databases cannot determine true incidence rates (AAPS, 2026). That is the essential caveat for reading the table below: the surge is a reporting and awareness effect, not a measured rise in real-world complications.

By manufacturer, two firms carry nearly the entire MAUDE footprint — Allergan (Costa Rica), at roughly 347,508 reports, and Mentor (Texas) at 177,426 — with Sientra a distant third. The brand distribution maps to the two PMA portfolios:

The complication profile is the signature of a permanent aesthetic implant: capsular contracture (188,499 reports) and failure of implant (177,437 reports) dominate, followed by deformity/disfigurement (47,433) and seroma (8,870). These are the chronic mechanical-biologic complications — scar-tissue tightening, shell rupture, and fluid accumulation — that drive revision surgery, not the acute-failure modes seen in life-sustaining implants.

Separating Complication Volume From Cancer Risk

A reader of this data must distinguish three different signals that the raw counts can blur:

1. All-cause complication reports (capsular contracture, rupture, seroma, pain) — the 580,684-report MAUDE volume — reflect the large installed base and routine revision-surgery reporting.
2. BIA-ALCL cancer cases — the FDA's 1,380 unique cases and 64 deaths as of 6/30/2024 — are the rare, textured-implant-associated lymphoma that drove the Allergan BIOCELL recall. Risk estimates for textured implants range roughly from 1 in 300 to 1 in 1,000 (Blanchet, 2024).
3. Breast implant illness (BII) — systemic symptoms such as fatigue, joint pain, and cognitive complaints reported by some patients — is a reporting category the FDA began tracking separately; the FDA's February 6, 2025 update included medical-device reports for systemic symptoms received through June 30, 2024 (Breast Implant Safety Alliance).

Following the BIA-ALCL evidence and patient-advocacy pressure, the FDA in 2021 restricted the sale of breast implants to providers and patients who reviewed a boxed-warning patient decision checklist, and required a device card listing the implant's make and model — labeling controls layered on top of the existing PMA framework.

What This Means for Quality, Regulatory, and Aesthetic-Device Teams

The data supports four practical takeaways:

1. Treat the textured-implant segment as effectively closed in the U.S. The Allergan BIOCELL recall, the BIA-ALCL association, and the 73% textured-surface case share removed macro-textured implants from the U.S. market. New aesthetic-implant strategy is a smooth-surface PMA play, not a textured one.
2. Design post-market surveillance around capsular contracture and rupture. These two complication categories account for the dominant share of reports and revision-surgery burden; a PMA post-approval study program should weight long-term shell-integrity and capsular-status endpoints.
3. Do not conflate complication volume with cancer risk. The 580,684-report MAUDE volume is a complication-and-reporting signal; the BIA-ALCL risk is a separate, rare, textured-implant-specific cancer signal tracked by the FDA at far smaller absolute case counts. Conflating them distorts both risk communication and benefit-risk assessment.
4. Recognize manufacturer concentration. Allergan and Mentor carry the dominant MAUDE and PMA footprint; Sientra and smaller entrants (Ideal, Bimini, Tiger, Motiva) hold secondary positions. A practice's or distributor's recall and adverse-event exposure is concentrated in the two lead portfolios.

Breast implants are the device family where an aesthetic product acquired a cancer-safety label, where one manufacturer's textured line was removed worldwide, and where the MAUDE record runs above half a million reports across a decade. The public data — 39 enforcement actions with 16 Class I, 23 recall events, 1,380 BIA-ALCL cases, and 580,684 MAUDE reports — is the benchmark against which current breast-implant safety performance is measured.

Data sources: FDA device enforcement report database, FDA Medical Device Recall database, FDA 510(k) and PMA databases, FDA MAUDE adverse-event database, and FDA BIA-ALCL medical-device-report summary; analysis by MedDeviceGuide, run date 2026-06-15. The all-cause MAUDE death and injury counts are distinct from the FDA's cancer-specific BIA-ALCL case and death figures. MAUDE event-type counts reflect reports filed, not confirmed causal attributions. This article is educational and is not regulatory, quality-system, or medical advice for a specific product or patient.